Studies have revealed that the STING agonist DMXAA, either alone or in combination with gemcitabine, induces significant tumor regression in both in situ and subcutaneous mouse pancreatic cancer models (90). This evidence concerns the gene STING1 and familial pancreatic carcinoma.